Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition

Am J Cardiol. 2003 Mar 15;91(6):742-3. doi: 10.1016/s0002-9149(02)03420-3.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary*
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Blood Vessel Prosthesis Implantation*
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / surgery*
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Hirudins / administration & dosage*
  • Hirudins / adverse effects
  • Hirudins / analogs & derivatives*
  • Humans
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Peptide Fragments / administration & dosage*
  • Peptide Fragments / adverse effects
  • Peptide Fragments / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / administration & dosage
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use*
  • Recombinant Proteins / administration & dosage*
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use*
  • Stents*
  • Survival Rate

Substances

  • Anticoagulants
  • Hirudins
  • Peptide Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Recombinant Proteins
  • bivalirudin